1.
Acta Gastroenterol. Latinoam.
; 44(2): 138-53, 2014 Jun.
Artigo
em Espanhol
| BINACIS
| ID: bin-133450
2.
Acta gastroenterol. latinoam
; 44(2): 138-53, 2014 Jun.
Artigo
em Espanhol
| LILACS, BINACIS
| ID: biblio-1157438
3.
Adv Ther
; 17(4): 190-4, 2000.
Artigo
em Inglês
| MEDLINE
| ID: mdl-11185058
RESUMO
This multicenter, open-label study assessed the clinical efficacy and tolerability of the proton-pump inhibitor rabeprazole 20 mg once daily in 189 patients with functional dyspepsia and normal findings on upper endoscopy. The clinical efficacy rate was 86% after only 4 weeks of treatment, and symptoms remained under control at the end of 4 weeks without treatment. Rabeprazole was well tolerated and was associated with a low incidence (8%) of mild, transient adverse events.